Sublingual administration, which bypasses the gastrointestinal tract, appears to be equally effective as IM injections while being less invasive and more cost-efficientparticularly in patients with atrophic gastritis, post-gastrectomy status, or conditions that impair intrinsic factor-mediated absorption, where long-term intervention is often required
To offset these pressures, Ipsen has successfully launched Iqirvo (elafibranor) for primary biliary cholangitis and Bylvay (odevixibat) for rare liver diseases, and acquired multiple innovative pipeline assets in 2024
GHRP-2 and GHRP-6 Options Growth hormone releasing peptides 2 and 6 represent older options in the secretagogue category
Results: NIHSS drop 6 demonstrated strong predictive value for favorable outcomes(AUC 0.762, sensitivity 63%, specificity 82%).Patients achieving NIHSS drop 6(n = 235) had higher recanalization rates (98.3% vs
Symptoms of Slow Recovery: Muscle fatigue that lingers, decreased performance, a feeling of "heavy" legs, and delayed onset muscle soreness (DOMS) that overstays its welcome
